Market open
Gain Therapeutics/$GANX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Gain Therapeutics
Gain Therapeutics Inc is a biotechnology company developing novel small molecule therapeutics to treat diseases across several therapeutic areas, including, lysosomal storage disorders, central nervous system disorders, metabolic disorders, and oncology. The company's clinical-stage product candidate, GT-02287, is being developed for the treatment of GBA1 Parkinson's disease. The company uses its computational target and drug discovery platform, Magellan, to discover novel allosteric binding sites on proteins implicated in disease and to identify proprietary small molecules that bind these sites to modulate protein function and treat the underlying cause of the disease. Geographically, the company operates in Switzerland, Spain, the United States, and Australia.
Ticker
$GANX
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
24
Website
GANX Metrics
BasicAdvanced
$46M
-
-$0.89
0.19
-
Price and volume
Market cap
$46M
Beta
0.19
52-week high
$2.53
52-week low
$1.54
Financial strength
Current ratio
2.966
Quick ratio
2.851
Long term debt to equity
5.204
Total debt to equity
8.897
Management effectiveness
Return on assets (TTM)
-82.80%
Return on equity (TTM)
-204.95%
Valuation
Price to book
6.1
Price to tangible book (TTM)
6.21
Price to free cash flow (TTM)
-1.998
Growth
Earnings per share change (TTM)
-47.88%
3-year earnings per share growth (CAGR)
-13.25%
GANX News
AllArticlesVideos
Gain Therapeutics Announces Poster Presentation at AD/PD 2025
GlobeNewsWire·2 weeks ago
Gain Therapeutics Reports Financial Results for the Fourth Quarter and Year End 2024 and Provides Corporate Update
GlobeNewsWire·2 weeks ago
Gain Therapeutics Doses First Participant in Phase 1b Clinical Trial of GT-02287 in Parkinson's Disease
GlobeNewsWire·4 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Gain Therapeutics stock?
Gain Therapeutics (GANX) has a market cap of $46M as of April 08, 2025.
What is the P/E ratio for Gain Therapeutics stock?
The price to earnings (P/E) ratio for Gain Therapeutics (GANX) stock is 0 as of April 08, 2025.
Does Gain Therapeutics stock pay dividends?
No, Gain Therapeutics (GANX) stock does not pay dividends to its shareholders as of April 08, 2025.
When is the next Gain Therapeutics dividend payment date?
Gain Therapeutics (GANX) stock does not pay dividends to its shareholders.
What is the beta indicator for Gain Therapeutics?
Gain Therapeutics (GANX) has a beta rating of 0.19. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.